(Adnkronos) - Il segretario del Gruppo italiano per lo studio delle malattie infiammatorie croniche intestinali Massimo Claudio Fantini: ‘Fra sostenibilità e innovazione’ è stato scelto perché rispecchia ciò che stimato vivendo in questi anni. Abbiamo nuove tecniche diagnostiche e nuovi farmaci come non mai in precedenza. E questo implica una scelta di sostenibilità”. L’obbiettivo: avere Linee guida per cure più personalizzate.
Category
🗞
NewsTranscript
00:00This year, on the occasion of the 15th edition of the National Congress of the Italian Group
00:10for the Study of Inflammatory and Chronic Intestinal Diseases, we have chosen the theme
00:16Between Sustainability and Innovation because it reflects in fact what we are experiencing
00:23in these years, that is, we have a strong innovative push both in terms of new diagnostic
00:31techniques but we are also experiencing the entry of new drugs as a result of the research
00:39carried out in the last 20 years that are offering us doctors a wide range of drugs
00:47as never before and this obviously implies a choice, a choice that must be a choice
00:55of sustainability, we know that they are expensive drugs, we are fortunately in a country where
01:02the national health system takes care of these costs, now learning and having clear guidelines
01:10that can guide us in the choice of the most correct, most effective drug in a certain patient
01:18is the goal. We are starting to have, although we have not yet reached this target, we are starting
01:25to have important information that guides us in the choice, as well as we have
01:32available technologies that help us more and more to focus on the single patient,
01:39to be able to interpret and understand well what is the level of, let's say, severity of the disease,
01:46to what point is it in the natural history of the disease, in such a way as to be able to
01:51try more and more to make therapies as personalized as possible for our patients.
01:59The main message that this Congress wants to convey to patients is the availability of new therapies,
02:07the availability of new diagnostic techniques, the ever more advanced ability to identify
02:15the disease as early as possible, to identify in an ever more precise way
02:21what is the level of activity of the disease in such a way as to be able to identify the most correct
02:29and most appropriate therapies for the different needs of the patient. We are also becoming
02:35more and more aware of the fact that the issues related to the disease, therefore the point of view
02:42of the clinic, must increasingly draw closer to those that are the patient's prospects,
02:48who experience the disease in a very different way. Converting the patient's need
02:53with that which is the clinical need related to the patient's disease is essential to achieve
02:58what we define today as a holistic remission of the disease, which takes into account
03:06360 degrees both the aspect properly related to the disease but also
03:11the impact of the disease on the patient's quality of life.